Category Archives: Genetic Engineering

IMAGE:Cancer Biotherapy and Radiopharmaceuticals, published 10 times per online with open access options and in print, is under the editorial leadership of Co-Editors-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation... view more

Credit: Mary Ann Liebert, Inc., publishers

ew Rochelle, NY, April 6, 2015--Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a statistically significant increase in patient survival. Robert O. Dillman, MD, NeoStem, Inc., asserts that "overall survival" rather than "progression-free survival" should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials, in a provocative new article published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website until May 6, 2015.

In the article "Cancer Vaccines: Can They Improve Survival?" Dr. Dillman differentiates between the two key endpoints typically used to assess therapeutic cancer vaccines in clinical studies. As cancer vaccines are designed to stimulate an immune response to cancer cells and induce long-term memory recognition of a tumor, they may improve overall survival even if they do not appear to slow the progression of disease. Although measuring overall survival compared to progression-free survival would usually require longer clinical trials, overall survival may be the only relevant efficacy endpoint, the author concludes.

"This is a timely article considering the number of vaccine and antibody immunotherapy trials ongoing or planned," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham. "The conclusion that overall survival is the best clinical endpoint for efficacy in therapeutic vaccine and antibody immunotherapy trials in patients with metastatic cancer is based on an analysis of four completed trials."

About the Journal

Cancer Biotherapy and Radiopharmaceuticals , published 10 times per online with open access options and in print, is under the editorial leadership of Co-Editors-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham, and Robert K. Oldham, MD, CAMC-Teay's Valley Cancer Center. Cancer Biotherapy and Radiopharmaceuticals, celebrating 30 years in 2015, is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Tables of content and a sample issue may be viewed on the Cancer Biotherapy and Radiopharmaceuticals website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research, Human Gene Therapy, and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN) (http://www.genengnews.com), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

###

View original post here:
Can cancer vaccines prolong survival?

IMAGE:This is Charles Gersbach, assistant professor of biomedical engineering at Duke University. view more

DURHAM, N.C. -- Duke researchers have developed a new method to precisely control when genes are turned on and active.

The new technology allows researchers to turn on specific gene promoters and enhancers -- pieces of the genome that control gene activity -- by chemically manipulating proteins that package DNA. This web of biomolecules that supports and controls gene activity is known as the epigenome.

The researchers say having the ability to steer the epigenome will help them explore the roles that particular promoters and enhancers play in cell fate or the risk for genetic disease and it could provide a new avenue for gene therapies and guiding stem cell differentiation.

The study appears online April 6 in Nature Biotechnology.

"The epigenome is everything associated with the genome other than the actual genetic sequence, and is just as important as our DNA in determining cell function in healthy and diseased conditions," said Charles Gersbach, assistant professor of biomedical engineering at Duke. "That becomes immediately obvious when you consider that we have over 200 cell types, and yet the DNA in each is virtually the same. The epigenome determines which genes each cell activates and to what degree."

This genetic puppetmaster consists of DNA packaging proteins called histones and a host of chemical modifications -- either to these histones or the DNA itself -- that help determine whether a gene is on or off.

But Gersbach's team didn't have to modify the genes themselves to gain some control.

"Next to every gene is a DNA sequence called a promoter that controls its activity," explained Gersbach. "But there's also many other pieces of the genome called enhancers that aren't next to any genes at all, and yet they play a critical role in influencing gene activity too."

Timothy Reddy, assistant professor of biostatistics and bioinformatics at Duke, has spent the better part of a decade mapping millions of these enhancers across the human genome. There has not, however, been a good way to find out exactly what each one does. An enhancer might affect a gene next door or several genes across the genome -- or maybe none at all.

See the original post here:
Pulling the strings of our genetic puppetmasters

Bayers Marijn Dekkers (Christof Koepsel/Getty Images)

TOP STORIES

Endure if you must The Washington Posts takeout on tech gurus and venture capitalists with too much time on their hands trying to extend life (though most of the possible stuff they talk about are simply medical treatments not invented). Accompanying the story is a somewhat interesting game The Post created in which you drag stem cells into your brain and so on to extend your life.

I know its a week away but you should probably start watching the HIMSS 2015 hashtag now.

LIFE SCIENCE

A long but worthwhile read on a moratorium and proper path toward human genetic engineering.

In the long run, I believe the permissibility of using germline genomic modification to make babies will be, and should be, a political issue. Right now, I suspect I would opt for regulating it on a safety/benefit basis, allowing it only when the potential benefits outweighed the risks. But I might change my mind, either because of newly discovered facts or well-made arguments. Importantly, though I do not think that my view should govern. The people, through their governments, should govern.

Medtronic has invested $2 million in DreaMed Diabetes and will be using its artificial pancreas technology in is insulin pumps.

I hope you didnt miss The Wall Street Journals look at Bayer and its continued focus on its health and agriculture businesses. Bayer is dumping its $10 billion specialty plastics business.

Still, some analysts are skeptical that Bayers drug pipeline is strong enough to deliver many new products with selling power like the current wave. But Bayer expects at least three new drugs in midstage clinical testing, including two for chronic heart failure, to advance this year. Strong data is expected for those trials, said Ali Al-Bazergan, an analyst at Datamonitor Healthcare in London.

View original post here:
Going deep on life extension investments and human genetic engineering (Morning Read)

Genetic Engineering Legality
This video is about Genetic Engineering Legality.

By: Mira Rajani

More here:
Genetic Engineering Legality - Video

Mixing Human DNA Animal DNA Genetic engineering Last days news
hy, please like and subscribed for more videos,thank you for visiting here..

By: Anderson Silva

See the original post:
Mixing Human DNA Animal DNA Genetic engineering Last days news - Video

Genetic Engineering Technology
Discussion on my research topic for ENG 2010.

By: Guintah212

Read this article:
Genetic Engineering Technology - Video

What Is The Future Of Genetic Engineering?

By: Top Sites

See original here:
What Is The Future Of Genetic Engineering? - Video

Dark Agenda ~ Bio Genetic Engineering with Nanotechnology
Changing you and your world from within and without.

By: MrPurpleTie

See the original post here:
Dark Agenda ~ Bio Genetic Engineering with Nanotechnology - Video

Unidentifiable shopping trolley - Source: Breakfast

Cancer-fighting pink pineapples, heart-healthy purple tomatoes and less fatty vegetable oils may someday be on grocery shelves alongside more traditional products.

These genetically engineered foods could receive government approval in the coming years, following the OK given recently in the US to apples that don't brown and potatoes that don't bruise.

The companies and scientists that have created these foods are hoping that customers will be attracted to the health benefits and convenience and overlook any concerns about genetic engineering.

"I think once people see more of the benefits they will become more accepting of the technology," says Michael Firko, who oversees the US Agriculture Department's regulation of genetically modified organisms, or GMOs.

Critics aren't so sure. They say there should be more thorough regulation of modified foods, which are grown from seeds engineered in labs, and have called for mandatory labeling of those foods. The Agriculture Department only has the authority to oversee plant health of GMOs, and seeking Food and Drug Administration's safety approval is generally voluntary.

"Many of these things can be done through traditional breeding," says Doug Gurian-Sherman of the advocacy group Center for Food Safety. "There needs to be skepticism."

What could be coming next? Del Monte has engineered a pink pineapple that includes lycopene, an antioxidant compound that gives tomatoes their red color and may have a role in preventing cancer. USDA has approved importation of the pineapple, which would be grown only outside of the United States; it is pending FDA approval.

A small British company is planning to apply for US permission to produce and sell purple tomatoes that have high levels of anthocyanins, compounds found in blueberries that some studies show lower the risk of cardiovascular disease and cancer. FDA would have to approve any health claims used to sell the products.

Seed giants Monsanto and Dow AgroSciences are separately developing modified soybean, canola and sunflower oils with fewer saturated fats and more Omega-3 fatty acids. The Florida citrus company Southern Gardens is using a spinach gene to develop genetically engineered orange trees that could potentially resist citrus greening disease, which is devastating the Florida orange crop. Okanagan Specialty Fruits Inc., the company that created the non-browning apples, is also looking at genetically engineering peaches, cherries and apples to resist disease and improve quality.

Originally posted here:
Cancer-fighting pink pineapples? Genetic engineering looms

Illuminati Science EXPOSED Genetic Engineering, Cloning, DNA Manipulation, Transhumanism 1080p
I am just a middleman trying to spread the word FAIR USE NOTICE: This video may contain copyrighted material. Such material is made available for entertainment purposes only. This constitutes...

By: Timothy anon

See the original post here:
Illuminati Science EXPOSED Genetic Engineering, Cloning, DNA Manipulation, Transhumanism 1080p - Video